Please type a plus sign (+) inside this

PTO/SB/05 (11-00)

use through 10/31/2002. OMB 0651-0032

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

UTILITY PATENT APPLICATION **TRANSMITTAL**

14538A-005111US Attorney Docket No. Koff, Andrew First Inventor

(Only for new nonprovisional applications under 37 C.F.R. § 1.53(b))

METHODS FOR ENHANCING ANIMAL GROWTH AND CELL PROLIFERATION BY ELIMINATION OF THE CYCLIN-DEPENDEN KINASE INHIBITOR FUNCTION OF P27KIP1

Express Mail Label No. ET949700515US APPLICATION ELEMENTS Assistant Commissioner for Patents ADDRESS TO **Box Patent Application** See MPEP chapter 600 concerning design patent application contents. Washington, DC 20231 CD-ROM or CD-R in duplicate, large table or Fee Transmittal Form (e.g., PTO/SB/17) (Submit an original and a duplicate for fee processing) Computer Program (Appendix) 2. 🛛 Applicant claims small entity status. 8. Nucleotide and/or Amino Acid Sequence Submission See 37 CFR 1.27. (if applicable, all necessary) з. 🔯 Specification [Total Pages L a. Computer Readable Form (CRF) (preferred arrangement set forth below) b. Specification Sequence Listing on: - Descriptive title of the Invention CD-ROM or CD-R (2 copies); or - Cross References to Related Applications ii. paper number of pages - Statement Regarding Fed sponsored R & D c.

Statements verifying identity of above copies - Reference to sequence listing, a table, or a computer program listing appendix **ACCOMPANYING APPLICATIONS PARTS** - Background of the Invention - Brief Summary of the Invention 9. 🔲 Assignment Papers (cover sheet & document(s)) - Brief Description of the Drawings (if filed) 10. 37 C.F.R.§3.73(b)Statement ☐ Power of - Detailed Description (when there is an assignee) - Claim(s) Attorney - Abstract of the Disclosure 11. 🔲 English Translation Document (if applicable) 4. Drawing(s) (35 U.S.C.113) [Total Sheets 15 12. Information Disclosure ☐ Copies of IDS 1 Statement (IDS)/PTO-1449 Citations 5. Oath or Declaration [Total Pages 13. 🔲 **Preliminary Amendment** 14. 🛛 Return Receipt Postcard (MPEP 503) b. Copy from a prior application (37 CFR 1.63 (d)) (Should be specifically itemized) (for a continuation/divisional with Box 18 completed) 15. 🔲 Certified Copy of Priority Document(s) i. DELETION OF INVENTOR(S) (if foreign priority is claimed) Signed statement attached deleting inventor(s) 16. 🗍 Nonpublication Request under 35 U.S.C. named in the prior application, see 37 CFR 122(b)(2)(B)(i). Applicant must attach form PTO/SB/35 1.63(d)(2) and 1.33(b). or its equivalent 6. Application Data Sheet. See 37 CFR 1.76 17. 🛛 Other: Application cover page; Cert. of Mailing 18. If a CONTINUING APPLICATION, check appropriate box, and supply the requisite information below and in a preliminary amendment, or in an Application Data Sheet under 37 CFR 1.76: □ Continuation □ Divisional ☐ Continuation-in-part (CIP) of prior application No: 08/973,823 Prior application information: Examiner R. Shukla Group Art Unit: 1632 For CONTINUATION or DIVISIONAL APPS only: The entire disclosure of the prior application, from which an oath or declaration is supplied under Box 5b, is considered a part of the disclosure of the accompanying continuation or divisional application and is hereby incorporated by reference. The incorporation can only be relied upon when a portion has been inadvertently omitted from the submitted application parts. 19. CORRESPONDENCE ADDRESS □ Customer Number or Bar Code Label 20350 or 🔲 Correspondence address below (Insert Customer No. or Attach bar code label here) Name Address City State Zip Code Country Telephone Name (Print/Type) Mark G. Sandbaken, Ph.D. Registration No. (Attorney/Agent) 39,354 Signature Date 01-04-02

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.SE 5011378 v1



13

: 5

L

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

INVENTOR:	Andrew Koff Hiroaki Kiyokawa	
ASSIGNEE:	Sloan-Kettering Institute for Cancer Research	
APPLICATION NO.:	n/a	GAU: n/a
FILING DATE:	January 4, 2002	
TITLE:	METHODS FOR ENHANCING ANIMAL GROWTH AND CELL PROLIFERATION BY ELIMINATION OF THE CYCLIN- DEPENDENT KINASE INHIBITOR FUNCTION OF P27 ^{Kip1}	
ATTORNEY DOCKET:	14538A-005111US	
Assistant Commissioner for Patents Box PATENT APPLICATION Washington, D.C. 20231		
CERTIFICATE OF MAILING (Express Mail)		
Honorable Assistant Commissioner:		
I hereby certify that the attached correspondence [U.S. PATENT APPLICATION] is being deposited with the United States Postal Service as "Express Mail Post Office to Addressee," Express Mail Label No. ET949700515US (according to C.F.R. §1.10) on this 4 th day of January, 2002 with sufficient postage and in an envelope addressed to the Assistant Commissioner for Patents, Box PATENT APPLICATION, Washington, D.C. 20231.		
	Signature of registered properson actually making the to 37 C.F.R. §1.10(b).	actitioner or other e deposit pursuant
	Susan Foley Name of person signing a	bove